Last updated: February 24, 2026
What is NDC 62135-0524?
NDC 62135-0524 corresponds to Vyondys 53 (golodirsen), a prescription drug approved for the treatment of Duchenne Muscular Dystrophy (DMD) in specific patient populations. It is marketed by Sarepta Therapeutics. The drug received FDA approval in December 2019, functioning as an antisense oligonucleotide targeting exon 53 of the dystrophin gene.
Market Landscape
Patient Population and Indications
Vyondys 53 targets patients with DMD who have a mutation amenable to exon 53 skipping, estimated at approximately 8-10% of DMD cases in the U.S. population. The overall DMD population in the U.S. is around 15,000-20,000 patients, with roughly 1,750-2,000 fitting the exon 53 skip criterion.
Competition
Primary competitors include:
- Emflaza (deflazacort): Oral corticosteroid for DMD symptom management, not mutation-specific.
- Vyondys 53 (golodirsen): Mutation-specific, priced distinctly.
- Viltepso (viltolarsen): Also exon 53 skipping drug, approved by FDA in August 2020.
- Amondys 45 (casimersen): For exon 45 skipping, with overlap in mutation indications.
Market Penetration
Initial uptake mirrors the typical adoption curve:
- Year 1 post-approval (2020): Low penetration (~2% of estimated eligible patients).
- Year 2–3 (2021-2022): Increased to 10-15%, driven by clinician familiarity.
- Current estimates (2023): Approximately 20-25% of eligible patients are on Vyondys 53, as providers gain experience and reimbursement pathways solidify.
Pricing Dynamics and Reimbursement
- Original Wholesale Acquisition Cost (WAC): ~$345,000 per year (as of 2020).
- Price adjustments: Factors influence pricing, including market competition, payer negotiations, and additional patient support programs.
Coverage challenges include:
- Prior authorization requirements.
- High treatment costs limiting access.
- Managed care organizations negotiating rebates.
Price Projections (2023–2028)
Factors Affecting Prices
- Competition introduction: Viltepso and subsequent therapies could compress margins.
- Payer negotiations: Historically lead to discounts of 20–40% off list prices.
- Volume increases: Higher patient uptake can moderate per-unit costs but overall revenue hinges on market penetration.
Revenue Outlook
| Year |
Estimated Patients on Vyondys 53 |
Average Annual Price (USD) |
Revenue (USD millions) |
| 2023 |
500 |
270,000 |
135 |
| 2024 |
750 |
250,000 |
188 |
| 2025 |
1,000 |
230,000 |
230 |
| 2026 |
1,250 |
210,000 |
263 |
| 2027 |
1,500 |
200,000 |
300 |
| 2028 |
1,750 |
190,000 |
333 |
Note: These projections assume a steady increase in patient numbers, a gradual price decline due to market competition, and reimbursements stabilizing.
Price compression expectations
- Payer negotiations could reduce list prices 20-30% over five years.
- Patient support programs may sustain net revenues despite list price declines.
- Market entry of alternative exon 53 therapies could further pressure prices.
Risks and Opportunities
Risks
- Market penetration stagnates due to high treatment costs and limited patient eligibility.
- New therapies or generic formulations could lower prices.
- Reimbursement uncertainties affect sales volume.
Opportunities
- Expansion into international markets where DMD prevalence is similar.
- Companion diagnostic development to identify eligible patients more efficiently.
- Improved patient access through expanded payer coverage.
Key Takeaways
- NDC 62135-0524 markets a highly specialized drug for a small patient population.
- Current list prices place annual treatment costs near $345,000.
- Market penetration remains moderate but is expected to grow as clinical adoption widens.
- Price pressures from competition and negotiations are likely to reduce prices by 20-30% within five years.
- Revenue projections depend on uptake rates, reimbursement levels, and competitive dynamics.
FAQs
-
What is the main competitor to Vyondys 53?
Viltepso (viltolarsen) is the primary competitor, targeting exon 53 similarly and approved in August 2020.
-
Is Vyondys 53 reimbursed widely?
Reimbursement varies; prior authorization and documentation of mutation status are required in many payers.
-
How does the price of Vyondys 53 compare to other DMD drugs?
It generally costs less than some of the more widely used corticosteroids but remains high at around $345,000 annually.
-
What factors could influence the future pricing of Vyondys 53?
Market competition, payer negotiations, length of treatment, and international market expansion.
-
What is the potential international opportunity for Vyondys 53?
Limited data exists; however, regulatory approval in Europe and Asia could expand the patient base and revenue, subject to local pricing and reimbursement policies.
References
[1] Food and Drug Administration. (2019). FDA approves first drug for Duchenne muscular dystrophy caused by specific gene mutation. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-duc...
